

CellGenix Appoints Dr. Till Puschmann as Vice President R&D & Business Development and Member of the Management Team

CellGenix, a global manufacturing leader of GMP-grade raw materials for cell therapy, gene therapy and tissue-engineered products, is pleased to announce the appointment of Dr. Till Puschmann as Vice President R&D and Business Development and member of the management team.

Till joined CellGenix in 2018 as Business Development & Senior Project Manager. As Vice President R&D and Business Development, Till is responsible for the development of CellGenix' product portfolio and broadening of the pipeline. He also still acts as Senior Project Manager steering and supporting interdepartmental projects. The management team is completed by Prof. Dr. med. Felicia M. Rosenthal (Chief Executive Officer), Frank Hecht (Vice President Marketing & Sales), Dr. Bernd Leistler (Vice President Production) and Dr. Udo Nirenberg (Vice President Quality Management).

“We are delighted to welcome Dr. Puschmann in our management team,” said Prof. Felicia Rosenthal, CEO of CellGenix. “Till’s experience includes a valuable combination of science, entrepreneurship and business know-how. I am confident that he will prove to be an important addition to our management team as CellGenix continues to expand and build on its leading position as premium supplier of high-quality raw materials for cell and gene therapy manufacturing. We welcome him in our management team and look forward to continue working with him.”

“Receiving the invitation to become member of the management team was very exciting news. I will strive to continuously improve the two areas of CellGenix’ departments I have been entrusted with. As head of Business Development, it is my goal to extend and broaden our portfolio and technology base and to support CellGenix’ various projects with my know-how and expertise. I am also very excited to put my scientific background at the disposal of our experienced R&D team in order to continue the development of high quality products for our customers in the cell and gene therapy market.”

Till spent five years in Gothenburg, Sweden as a postdoctoral researcher at the University and was founder and CEO of an innovative biotech company focused on neural 3D cell culture systems. He has authored more than ten research publications (some in high-impact journals) and holds several patents. Before joining CellGenix in Freiburg in 2018 he served as management consultant for the pharma industry in the U.S. where he gained deeper insights in large pharma’s processes and structures. He holds a Diploma degree in biochemistry from the Free University Berlin, Germany, and received his Ph.D. in neurosciences from the University of Melbourne, Australia.

About CellGenix

CellGenix is a leading manufacturer and developer of premium-grade reagents for clinical cell culture needs. The company has more than two decades of in-house expertise in GMP manufacturing and development of products in the field of cell therapy, gene therapy and regenerative medicine. The superior quality GMP reagents are used by leading experts and are proven in clinical trials and commercial manufacturing throughout the world. CellGenix is

headquartered in Freiburg, Germany and operates a subsidiary in Portsmouth, New Hampshire, USA, serving the North American market.

Contact:

CellGenix GmbH

Prof. Dr. med. Felicia M. Rosenthal

Chief Executive Officer

T.:+49 761 88889100

E.:publicrelations@cellgenix.com

www.cellgenix.com